Twin Capital Management Inc. Has $3.35 Million Stake in Boston Scientific Corporation $BSX

Twin Capital Management Inc. reduced its holdings in Boston Scientific Corporation (NYSE:BSX) by 17.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,301 shares of the medical equipment provider’s stock after selling 7,227 shares during the quarter. Twin Capital Management Inc.’s holdings in Boston Scientific were worth $3,349,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Steph & Co. acquired a new stake in shares of Boston Scientific in the third quarter worth $25,000. Financial Consulate Inc. bought a new position in Boston Scientific during the third quarter worth $25,000. United Community Bank raised its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Finally, Kilter Group LLC acquired a new position in Boston Scientific during the 2nd quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

Boston Scientific Trading Down 1.8%

Shares of BSX opened at $76.24 on Friday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a market cap of $113.02 billion, a PE ratio of 39.30, a PEG ratio of 1.37 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $74.86 and a 1 year high of $109.50. The stock has a 50 day simple moving average of $93.39 and a 200-day simple moving average of $98.79.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business’s revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday. Robert W. Baird cut their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday. Stifel Nicolaus reduced their price objective on Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Royal Bank Of Canada lowered their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $109.43.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.